Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
12.58
+0.15 (1.21%)
At close: Dec 5, 2025, 4:00 PM EST
14.00
+1.42 (11.29%)
After-hours: Dec 5, 2025, 7:59 PM EST
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $14.54M in the quarter ending September 30, 2025, a decrease of -5.71%. This brings the company's revenue in the last twelve months to $55.78M, down -9.21% year-over-year. In the year 2024, Ocular Therapeutix had annual revenue of $63.72M with 9.03% growth.
Revenue (ttm)
$55.78M
Revenue Growth
-9.21%
P/S Ratio
39.14
Revenue / Employee
$203,588
Employees
274
Market Cap
2.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
| Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
| Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
| Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
| Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OCUL News
- 1 day ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 2 months ago - Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript - Seeking Alpha
- 2 months ago - Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint - GlobeNewsWire